



Smart

PA

Clinical Edit Criteria

Drug/Drug Class: **Corlanor® (ivabradine) Clinical Edit**
 Date: **December 3, 2018**
 Prepared for: **MO HealthNet**
 Prepared by: **Conduent-Heritage**

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Corlanor® (ivabradine) tablets.

Why was this Issue Selected:

Corlanor® (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with a left ventricular ejection fraction (LVEF) ≤35%, who are in sinus rhythm with resting heart rate ≥70 bpm and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Corlanor® was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that are intended to treat a serious disease or condition and may provide a significant improvement over available therapy. It was also granted fast track designation, which helps facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and fill an unmet medical need.

Program-Specific information

10/2017 - 9/2018 FFS

Drug	Claims	Spend
• Corlanor	424	\$169,522.30

Setting & Population: All MO HealthNet Participants

Type of **Increased risk of ADE** **Non-Preferred Agent**

Clinical Edit Criteria Proposal

Criteria:

Appropriate Indications

Data Sources: **Only administrative databases**

Databases + Prescriber-supplied

Setting and Population

- Drug class for review: Heart Failure
- Age range: All adult participants

Approval Criteria

- Left ventricular ejection fraction 35% or less who are in
 - sinus rhythm and
 - have a resting heart rate of at least 70 beats per minute
- On maximally tolerated doses of Beta Blockers or have a contraindication to Beta Blockers
- Must meet both 1 and 2 criteria
- Documented compliance on current therapy regimen

Denial Criteria

- Therapy will be denied if no approval criteria are met